| For: |
Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i40/5118.htm |
| Number | Citing Articles |
| 1 |
Hui Ye, Yu Liu, Ning Li, Jing Yu, Hong Cheng, Jiang Li, Xue-Zhi Zhang. Anti-<italic>Helicobacter pylori</italic> activities of <italic>Chenopodium ambrosioides</italic> L. <italic>in vitro</italic> and <italic>in vivo</italic>. World Journal of Gastroenterology 2015; 21(14): 4178-4183 doi: 10.3748/wjg.v21.i14.4178
|
| 2 |
Yong Xie, Xiaolin Pan, Yan Li, Huahong Wang, Yiqi Du, Jianming Xu, Jiangbin Wang, Zhirong Zeng, Ye Chen, Guoxin Zhang, Kaichun Wu, Dongsheng Liu, Nonghua Lv. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018; 73(6) doi: 10.1093/jac/dky056
|
| 3 |
Ju Yup Lee, Kyung Sik Park. Optimal First-Line Treatment forHelicobacter pyloriInfection: Recent Strategies. Gastroenterology Research and Practice 2016; 2016 doi: 10.1155/2016/9086581
|
| 4 |
Yuemiao Zhang, Wen Gao, Hong Cheng, Xuezhi Zhang, Fulian Hu. Tetracycline‐ and Furazolidone‐containing Quadruple Regimen as Rescue Treatment for Helicobacter pylori Infection: A Single Center Retrospective Study. Helicobacter 2014; 19(5) doi: 10.1111/hel.12143
|
| 5 |
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistance. Alimentary Pharmacology & Therapeutics 2016; 43(4) doi: 10.1111/apt.13497
|
| 6 |
Hassan Salmanroghani, Massoud Mirvakili, Mahmud Baghbanian, Roham Salmanroghani, Golshid Sanati, Pouria Yazdian, John Green. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLOS ONE 2018; 13(6) doi: 10.1371/journal.pone.0197096
|
| 7 |
Lan Li, Yini Ke, Chaohui Yu, Guogang Li, Ningmin Yang, Jianzhong Zhang, Youming Li. Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years. Helicobacter 2017; 22(3) doi: 10.1111/hel.12373
|
| 8 |
Nong-Rong Wang, Nong-Hua Lu, Ning-Jian Xu, Cai-Bin Huang, Dong-Sheng Liu, Jiu-Hong Ma, Xing-Xing He, Xiao-Qing Li, Jian-Bo Wen, Xue-Ping Zeng, Jian-Hua Tang, Hui-Zhen Fan, Xiao-Bai Guo, Xu Shu, Zhen Yang, Zhi-Fa Lu, Hong Zhou, Yin Zhu, Yong Xie. Furazolidone-based triple and quadruple eradication therapy for <italic>Helicobacter pylori</italic> infection. World Journal of Gastroenterology 2014; 20(32): 11415-11421 doi: 10.3748/wjg.v20.i32.11415
|
| 9 |
L. Wang, Z. Lin, S. Chen, J. Li, C. Chen, Z. Huang, B. Ye, J. Ding, W. Li, L. Wu, Y. Jiang, L. Meng, Q. Du, J. Si. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection 2017; 23(6) doi: 10.1016/j.cmi.2016.12.032
|
| 10 |
Silvio K. Ogata, Anita P. Ortiz Godoy, Francy R. da Silva Patricio, Elisabete Kawakami. High Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition 2013; 56(6) doi: 10.1097/MPG.0b013e31828b3669
|
| 11 |
Kateryna Plotnikova, Liliya Dubenska, Petro Rydchuk, Solomiya Pysarevska, Mariana Rydchuk, Sophia Ivakh, Dmytro Yanovych, Zvenyslava Zasadna, Serhiy Plotycya. Voltammetric determination of 5-nitroimidazole derivatives in honey and HPLC-MS/MS confirmation. Journal of Food Measurement and Characterization 2022; 16(1) doi: 10.1007/s11694-021-01214-z
|
| 12 |
Khean-Lee Goh, Parasakthi Navaratnam. High Helicobacter pylori Resistance to Metronidazole but Zero or Low Resistance to Clarithromycin, Levofloxacin, and Other Antibiotics in Malaysia. Helicobacter 2011; 16(3) doi: 10.1111/j.1523-5378.2011.00841.x
|
| 13 |
Jinfeng Dai, Jing Zhao, Liqi Mao, Yue Hu, Bin Lv. Study on the value of antibiotic‑resistant gene detection in Helicobacter pylori in China. Experimental and Therapeutic Medicine 2022; 23(3) doi: 10.3892/etm.2022.11153
|
| 14 |
Erin Milner, Benjamin Stevens, Martino An, Victoria Lam, Michael Ainsworth, Preston Dihle, Jocelyn Stearns, Andrew Dombrowski, Daniel Rego, Katharine Segars. Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases. Frontiers in Microbiology 2021; 12 doi: 10.3389/fmicb.2021.689958
|
| 15 |
Peng Su, Youming Li, Hongzhang Li, Jiakun Zhang, Lang Lin, Qunying Wang, Feng Guo, Zizhong Ji, Jibo Mao, Wuheng Tang, Zhengchao Shi, Wei Shao, Junliang Mao, Xinjian Zhu, Xiaofeng Zhang, Yuefeng Tong, Huimin Tu, Mizu Jiang, Zhiyong Wang, Fengzhe Jin, Ningmin Yang, Jianzhong Zhang. Antibiotic Resistance of Helicobacter Pylori Isolated in the Southeast Coastal Region of China. Helicobacter 2013; 18(4) doi: 10.1111/hel.12046
|
| 16 |
A. Cosme, M. Montes, M. Martos, I. Gil, U. Mendarte, Y. Salicio, L. Piñeiro, M.T. Recasens, B. Ibarra, C. Sarasqueta, L. Bujanda. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013; 19(4) doi: 10.1111/j.1469-0691.2012.03844.x
|
| 17 |
Brandonn Lopera, Kellys Lemos, José Danilo Atehortúa, Joaquín Valencia-Cárdenas, Diego Vélez-Gómez, Alonso Martinez, Tania Pérez-Cala, Beatriz Salazar. Furazolidone susceptibility of Helicobacter pylori isolated from patients with gastroduodenal diseases in Colombia. Revista do Instituto de Medicina Tropical de São Paulo 2025; 67 doi: 10.1590/s1678-9946202567020
|
| 18 |
Qizhi Cao, Xavier Didelot, Zhongbiao Wu, Zongwei Li, Lihua He, Yunsheng Li, Ming Ni, Yuanhai You, Xi Lin, Zhen Li, Yanan Gong, Minqiao Zheng, Minli Zhang, Jie Liu, Weijun Wang, Xiaochen Bo, Daniel Falush, Shengqi Wang, Jianzhong Zhang. Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis. Gut 2015; 64(4) doi: 10.1136/gutjnl-2014-307345
|
| 19 |
Wen Zhong Liu, Yong Xie, Hong Cheng, Nong Hua Lu, Fu Lian Hu, Wan Dai Zhang, Li Ya Zhou, Ye Chen, Zhi Rong Zeng, Chong Wen Wang, Shu Dong Xiao, Guo Zong Pan, Pin Jin Hu. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. Journal of Digestive Diseases 2013; 14(5) doi: 10.1111/1751-2980.12034
|
| 20 |
Javad Shokri-Shirvani, Arash Rahbar, Mohammad Zamani. Resistance of <i>Helicobacter pylori</i> to furazolidone and levofloxacin: A viewpoint. World Journal of Gastroenterology 2017; 23(37): 6920-6922 doi: 10.3748/wjg.v23.i37.6920
|
| 21 |
Ling Ren, Hong Lu, Hai Yan Li, Ling Yin Zhu, Xiao Qing Xu, Li Yang Gu, Zhi Zheng Ge, Xiao Bo Li. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. Journal of Digestive Diseases 2014; 15(11) doi: 10.1111/1751-2980.12186
|
| 22 |
Zhijun Cao, Qi Chen, Wei Zhang, Xiao Liang, Jingxian Liao, Wenzhong Liu, Shudong Xiao, Hong Lu. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scandinavian Journal of Gastroenterology 2015; 50(10) doi: 10.3109/00365521.2015.1037345
|
| 23 |
Jia-Yue Wang, Xian-Zhu Zhou, Chan-Juan Wang, Shi-Han Xu, Hui-Yun Zhu, Yi-Qi Du. Helicobacter pylori antibiotic resistance in different regions of China: A systematic review and meta-analysis. World Chinese Journal of Digestology 2024; 32(1) doi: 10.11569/wcjd.v32.i1.71
|
| 24 |
Wei Zhang, Qi Chen, Xiao Liang, Wenzhong Liu, Shudong Xiao, David Y Graham, Hong Lu. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64(11) doi: 10.1136/gutjnl-2015-309900
|
| 25 |
Alessia Savoldi, Elena Carrara, David Y. Graham, Michela Conti, Evelina Tacconelli. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155(5) doi: 10.1053/j.gastro.2018.07.007
|
| 26 |
Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. World Journal of Gastroenterology 2018; 24(40): 4596-4605 doi: 10.3748/wjg.v24.i40.4596
|
| 27 |
Yongfu Shao, Yifan Lin, Bojun Wang, Min Miao, Guoliang Ye. Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021. Helicobacter 2022; 27(5) doi: 10.1111/hel.12920
|
| 28 |
Li-Yang Gu, Wei-Wei Lin, Hong Lu, Xiao-Yu Chen, Zhi-Zheng Ge, Xiao-Bo Li. Quadruple Therapy with Medications Containing Either Rufloxacin or Furazolidone as a Rescue regimen in the Treatment of Helicobacter pylori-Infected Dyspepsia Patients: A Randomized Pilot Study. Helicobacter 2011; 16(4) doi: 10.1111/j.1523-5378.2011.00848.x
|
| 29 |
Probiotics: mechanism of action and gastrointestinal health: gut guardians: unlocking the power of probiotics. Journal of the Science of Food and Agriculture 2026; 106(7) doi: 10.1002/jsfa.70275
|
| 30 |
Jyh-Ming Liou, Chi-Yang Chang, Mei-Jyh Chen, Chieh-Chang Chen, Yu-Jen Fang, Ji-Yuh Lee, Jeng-Yih Wu, Jiing-Chyuan Luo, Tai-Cherng Liou, Wen-Hsiung Chang, Cheng-Hao Tseng, Chun-Ying Wu, Tsung-Hua Yang, Chun-Chao Chang, Hsiu‐Po Wang, Bor-Shyang Sheu, Jaw-Town Lin, Ming-Jong Bair, Ming-Shiang Wu, Oliver Schildgen. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study. PLOS ONE 2015; 10(5) doi: 10.1371/journal.pone.0124199
|
| 31 |
Lei Li, FanDong Meng, Shengtao Zhu, ShuiLong Guo, YongJun Wang, Xin Zhao, YiLin Sun, Yan Zhang, QinQin Wang, HuFeng Xu, ShuTian Zhang, Srinivas Nammi. Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori. Evidence-Based Complementary and Alternative Medicine 2018; 2018(1) doi: 10.1155/2018/4320219
|
| 32 |
Hanafiah Alfizah, Ahmad Norazah, Razlan Hamizah, Mohamed Ramelah. Resistotype of Helicobacter pylori isolates: the impact on eradication outcome. Journal of Medical Microbiology 2014; 63(5) doi: 10.1099/jmm.0.069781-0
|
| 33 |
Juan Qian, Feng Ye, Jun Zhang, Yan‐Mei Yang, Hui‐Ming Tu, Qi Jiang, Li Shang, Xiao‐Lin Pan, Rui‐Hua Shi, Guo‐Xin Zhang. Levofloxacin‐containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for Helicobacter pylori Eradication in China. Helicobacter 2012; 17(6) doi: 10.1111/j.1523-5378.2012.00993.x
|
| 34 |
Yongfu Shao, Rongdan Lu, Yunben Yang, Qiancheng Xu, Bojun Wang, Guoliang Ye. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. Journal of Clinical Laboratory Analysis 2018; 32(4) doi: 10.1002/jcla.22339
|
| 35 |
Surekha Challa, Nageswara Rao Reddy Neelapu. Horizontal Gene Transfer. 2019; doi: 10.1007/978-3-030-21862-1_10
|
| 36 |
Huiyi Li, Xiao Liang, Qi Chen, Wei Zhang, Hong Lu. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. Scandinavian Journal of Gastroenterology 2018; 53(2) doi: 10.1080/00365521.2017.1413132
|
| 37 |
Guodong Liu, Xiwei Xu, Lihua He, Zhaolu Ding, Yixin Gu, Jianzhong Zhang, Liya Zhou. Primary Antibiotic Resistance of Helicobacter pylori Isolated from Beijing Children. Helicobacter 2011; 16(5) doi: 10.1111/j.1523-5378.2011.00856.x
|
| 38 |
Surekha Challa, Titash Dutta, Pallaval Veera Bramhachari, Neelapu Nageswara Rao Reddy. Implication of Quorum Sensing and Biofilm Formation in Medicine, Agriculture and Food Industry. 2019; doi: 10.1007/978-981-32-9409-7_8
|
| 39 |
|
| 40 |
Huifen Wang, Wei Wei, Fang Liu, Miao Wang, Yanli Zhang, Shiyu Du. Effects of fucoidan and synbiotics supplementation during bismuth quadruple therapy of Helicobacter pylori infection on gut microbial homeostasis: an open-label, randomized clinical trial. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1407736
|
| 41 |
Hong Li, Yalin Shen, Xiaona Song, Xiaoqiong Tang, Renwei Hu, Barry James Marshall, Hong Tang, Mohammed Benghezal. Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing. Helicobacter 2022; 27(2) doi: 10.1111/hel.12873
|
| 42 |
Chih-Chieh Huang, Kuo-Wang Tsai, Tzung-Jiun Tsai, Ping-I Hsu. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomarker Research 2017; 5(1) doi: 10.1186/s40364-017-0103-x
|
| 43 |
Jian Zhang, Chuan Han, Wen Quan Lu, Na Wang, Si Ran Wu, Yong Xi Wang, Jin Ping Ma, Jie Hong Wang, Cheng Hao, Dong Hong Yuan, Na Liu, Yong Quan Shi. A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment. Journal of Digestive Diseases 2020; 21(5) doi: 10.1111/1751-2980.12870
|
| 44 |
Fayaz Ahmad Wani, Gulnaz Bashir, Mushtaq Ahmad Khan, Showkat Ali Zargar, Zubaida Rasool, Qurteeba Qadri. Antibiotic Resistance in Helicobacter pylori: A Mutational Analysis from a Tertiary Care Hospital in Kashmir, India. Indian Journal of Medical Microbiology 2018; 36(2) doi: 10.4103/ijmm.IJMM_18_19
|
| 45 |
Ferdane Sapmaz, Ismail H. Kalkan, Pinar Atasoy, Sebahat Basyigit, Sefa Guliter. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. American Journal of Therapeutics 2017; 24(4) doi: 10.1097/MJT.0000000000000316
|
| 46 |
Jennifer Li, Xian-Zhi Li. Efflux-Mediated Antimicrobial Resistance in Bacteria. 2016; doi: 10.1007/978-3-319-39658-3_19
|
| 47 |
Jingxian Liao, Qing Zheng, Xiao Liang, Wei Zhang, Qinjuan Sun, Wenzhong Liu, Shudong Xiao, David Y. Graham, Hong Lu. Effect of Fluoroquinolone Resistance on 14‐day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy. Helicobacter 2013; 18(5) doi: 10.1111/hel.12052
|
| 48 |
Binjie Hu, Fuju Zhao, Shiwen Wang, Michal A Olszewski, Haipeng Bian, Yong Wu, Mimi Kong, Lingli Xu, Yingxin Miao, Yi Fang, Changqing Yang, Hu Zhao, Yanmei Zhang.
A High-Throughput Multiplex Genetic Detection System for
Helicobacter Pylori
Identification, Virulence and Resistance Analysis
. Future Microbiology 2016; 11(10) doi: 10.2217/fmb-2016-0023
|
| 49 |
Yuan Wenzhen, Zhao Peng, Guan Quanlin, Li Yumin. Is Culture Necessary before First-Line Treatment for Helicobacter pylori Infection?. Internal Medicine 2011; 50(21) doi: 10.2169/internalmedicine.50.5974
|
| 50 |
J. Huang, L. Zhou, L. Geng, M. Yang, X.‐W. Xu, Z.‐L. Ding, M. Mao, Z.‐L. Wang, Z.‐L. Li, D.‐Y. Li, S.‐T. Gong. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children–a multicentre, open‐labelled study. Alimentary Pharmacology & Therapeutics 2013; 38(10) doi: 10.1111/apt.12516
|
| 51 |
Chuan Xie, Nong‐Hua Lu. Review: Clinical Management of Helicobacter pylori Infection in China. Helicobacter 2015; 20(1) doi: 10.1111/hel.12178
|
| 52 |
Tiing Leong Ang, Luokai Wang, Daphne Ang, Priscilla Chiam, Kwong Ming Fock, Eng Kiong Teo. Is there still a role for empiric first‐line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. Journal of Digestive Diseases 2013; 14(2) doi: 10.1111/1751-2980.12024
|
| 53 |
Maria Pina Dore, Hong Lu, David Y Graham. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65(5) doi: 10.1136/gutjnl-2015-311019
|
| 54 |
Xiao Liang, Xiaoqing Xu, Qing Zheng, Wei Zhang, Qinjuan Sun, Wenzhong Liu, Shudong Xiao, Hong Lu. Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study. Clinical Gastroenterology and Hepatology 2013; 11(7) doi: 10.1016/j.cgh.2013.01.008
|
| 55 |
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
|
| 56 |
Fangyuan Dong, Danian Ji, Renxiang Huang, Fan Zhang, Yiqin Huang, Ping Xiang, Mimi Kong, Li Nan, Xianping Zeng, Yong Wu, Zhijun Bao. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. Medicine 2015; 94(47) doi: 10.1097/MD.0000000000002056
|